Literature DB >> 2506947

New variant of von Willebrand disease with defective binding to factor VIII.

M Nishino1, J P Girma, C Rothschild, E Fressinaud, D Meyer.   

Abstract

A new variant of von Willebrand disease (vWD) was identified by a new analytic method which characterizes the ability of plasma von Willebrand Factor (vWF) to bind to purified factor VIII (F.VIII). vWF was isolated from small amounts of plasma by immunoadsorption with a selected monoclonal antibody to vWF previously coated onto wells of microtitration plates. Plasma F.VIII was removed from immobilized vWF by washing with 0.4 mol/L CaCl2; purified F.VIII was then added to the well. The amount of bound F.VIII was estimated directly in the wells by a chromogenic assay and immobilized vWF was estimated by an immunologic a pool of normal plasma, ten control individuals, 13 with hemophilia A and five with type I vWD. In all cases, the dose-response curves were linear and the slopes of the regression lines were essentially the same. The method was then applied to investigate the binding of vWF to F.VIII in two vWD patients (sister and brother) who demonstrated significantly lower activity of F.VIII than of vWF. The first patient, with a long history of epistaxis, bruising, and hematomas, showed a slightly prolonged bleeding time (10 minutes); 15% VIII:C and 39% of vWF:Ag and vWFRCo. Her brother, who has a bleeding syndrome but no hematomas, showed similar data (bleeding time 9 minutes, 20% VIII:C, 53% vWF:Ag and vWFRCo). Similar levels of F.VIII were observed in the two propositi by four different methods (one- and two-stage clotting and chromogenic and immunologic assays). Sodium dodecyl sulfate (SDS) 1.4% agarose gel electrophoresis showed that all multimers of vWF were present in both patients. vWF binding to F.VIII was markedly decreased in the two propositi. The abnormal binding of vWF to F.VIII was not corrected during pregnancy or after infusion of 1-deamino (8-D-arginine) vasopressin despite an increase in vWF levels. The qualitative abnormality of vWF in both patients was associated with a subtle alteration of the multimeric structure by SDS 3% agarose gel electrophoresis in which the two central subbands of the quintuplet of individual oligomers were undetectable or poorly visible. SDS-polyacrylamide gel electrophoresis under reducing conditions demonstrated a single band of 275 Kd in the plasma of both patients, and there was no evidence of a second band corresponding to pro-vWF, the precursor of the mature vWF subunit, suggesting that proteolytic processing of vWF was normal.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506947

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Von Willebrand disease.

Authors:  R Schneppenheim
Journal:  Eur J Pediatr       Date:  1996-09       Impact factor: 3.183

Review 2.  Laboratory diagnosis of von Willebrand disease.

Authors:  J C Roberts; V H Flood
Journal:  Int J Lab Hematol       Date:  2015-05       Impact factor: 2.877

3.  A common ancestor more than 10,000 years old for patients with R854Q-related type 2N von Willebrand's disease in Italy.

Authors:  Alessandra Casonato; Viviana Daidone; Giovanni Barbon; Elena Pontara; Irene Di Pasquale; Lisa Gallinaro; Letizia Marullo; Giorgio Bertorelle
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

Review 4.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

Review 5.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

6.  Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.

Authors:  B Boylan; A S Rice; C De Staercke; M E Eyster; H M Yaish; C M Knoll; C J Bean; C H Miller
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

Review 7.  Von Willebrand's disease.

Authors:  I M Nilsson; S Lethagen
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

8.  Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.

Authors:  Matthew P Kosloski; Aaron Peng; Prashant R Varma; Anas M Fathallah; Razvan D Miclea; Donald E Mager; Sathy V Balu-iyer
Journal:  Drug Deliv       Date:  2010-11-30       Impact factor: 6.419

9.  The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.

Authors:  A Leyte; J Voorberg; H B Van Schijndel; B Duim; H Pannekoek; J A Van Mourik
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

10.  Hemophilia A or von Willebrand disease?

Authors:  J Batlle; M J Blanco-Lopez; M Domenech; M Baiget; R Rocha; M F Lopez-Fernandez
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.